These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 21784348)

  • 21. Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti-Amyloid-β Therapy.
    Agarwal A; Gupta V; Brahmbhatt P; Desai A; Vibhute P; Joseph-Mathurin N; Bathla G
    Radiographics; 2023 Sep; 43(9):e230009. PubMed ID: 37651273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
    Wang D; Kowalewski EK; Koch G
    Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
    Delnomdedieu M; Duvvuri S; Li DJ; Atassi N; Lu M; Brashear HR; Liu E; Ness S; Kupiec JW
    Alzheimers Res Ther; 2016 Mar; 8(1):12. PubMed ID: 26925577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications.
    Doran SJ; Sawyer RP
    Front Neurosci; 2024; 18():1326784. PubMed ID: 38312931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy.
    DiFrancesco JC; Longoni M; Piazza F
    Front Neurol; 2015; 6():207. PubMed ID: 26441825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.
    Carlson C; Estergard W; Oh J; Suhy J; Jack CR; Siemers E; Barakos J
    Alzheimers Dement; 2011 Jul; 7(4):396-401. PubMed ID: 21784350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
    Piazza F; Winblad B
    J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Aβ immunotherapy for Alzheimer's disease].
    Sakai K; Yamada M
    Brain Nerve; 2013 Apr; 65(4):461-8. PubMed ID: 23568994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice.
    Luo F; Rustay NR; Seifert T; Roesner B; Hradil V; Hillen H; Ebert U; Severin JM; Cox BF; Llano DA; Day M; Fox GB
    J Pharmacol Exp Ther; 2010 Dec; 335(3):580-8. PubMed ID: 20823195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model.
    Aldea R; Grimm HP; Gieschke R; Hofmann C; Lott D; Bullain S; Delmar P; Klein G; Lyons M; Piazza F; Carare RO; Mazer NA
    Alzheimers Dement (N Y); 2022; 8(1):e12306. PubMed ID: 35676943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease.
    Withington CG; Turner RS
    Front Neurol; 2022; 13():862369. PubMed ID: 35401412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prodromal Alzheimer's disease presenting as cerebral amyloid angiopathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-Aβ autoantibodies.
    Boncoraglio GB; Piazza F; Savoiardo M; Farina L; DiFrancesco JC; Prioni S; Tagliavini F; Parati EA; Giaccone G
    J Alzheimers Dis; 2015; 45(2):363-7. PubMed ID: 25537009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of 3- and 5-point severity scales to assess ARIA-E.
    Bracoud L; Klein G; Lyons M; Scelsi MA; Wojtowicz J; Bullain S; Purcell D; Fiebach JB; Barakos J; Suhy J
    Alzheimers Dement (Amst); 2023; 15(4):e12503. PubMed ID: 38026755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring Blood-Brain Barrier Integrity Following Amyloid-β Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model.
    Blockx I; Einstein S; Guns PJ; Van Audekerke J; Guglielmetti C; Zago W; Roose D; Verhoye M; Van der Linden A; Bard F
    J Alzheimers Dis; 2016 Sep; 54(2):723-35. PubMed ID: 27567811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies.
    Brashear HR; Ketter N; Bogert J; Di J; Salloway SP; Sperling R
    J Alzheimers Dis; 2018; 66(4):1409-1424. PubMed ID: 30412493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice.
    Cogswell PM; Barakos JA; Barkhof F; Benzinger TS; Jack CR; Poussaint TY; Raji CA; Ramanan VK; Whitlow CT
    AJNR Am J Neuroradiol; 2022 Sep; 43(9):E19-E35. PubMed ID: 35953274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid-related imaging abnormalities in AβPP duplication carriers.
    Chamard L; Wallon D; Pijoff A; Berger E; Viennet G; Hannequin D; Magnin E
    J Alzheimers Dis; 2013; 37(4):789-93. PubMed ID: 23948920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amyloid-related imaging abnormalities (ARIA) and their radiological, biological and clinical characteristics: a plain language summary.
    Hampel H; Elhage A; Cho M; Nicoll JA; Atri A
    Neurodegener Dis Manag; 2024 Jun; ():1-12. PubMed ID: 38949171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
    Liu E; Wang D; Sperling R; Salloway S; Fox NC; Blennow K; Scheltens P; Schmidt ME; Streffer J; Novak G; Einstein S; Booth K; Ketter N; Brashear HR;
    Neurology; 2018 Mar; 90(10):e877-e886. PubMed ID: 29429971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.